Search results for " relap"

showing 10 items of 130 documents

Salvage treatment for children with relapsed/refractory germ cell tumors: The Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) experienc…

2020

Background Malignant germ cell tumors (GCTs) are a heterogeneous group of rare neoplasms in children. Optimal outcome is achieved with multimodal therapies for patients with both localized and advanced disease, especially after the introduction of platinum-based chemotherapy regimens. In this respect, data on salvage treatment for children with relapsed or platinum-refractory disease are still limited. Methods Retrospective analysis of data regarding patients affected by malignant GCTs with platinum-refractory or relapsed disease after first-line treatment according to AIEOP TCGM 2004 protocol was conducted. Results Twenty-one patients, 15 females and 6 males, were considered for the analys…

OncologyMelphalanMalemedicine.medical_treatmentDrug ResistanceSalvage therapyrelapsed tumorsDeoxycytidineCarboplatinchemistry.chemical_compound0302 clinical medicineNeoplasmsAntineoplastic Combined Chemotherapy Protocolsgerm cell tumorsChildEtoposideIfosfamideRemission InductionHematologyNeoplasms Germ Cell and EmbryonalPrognosisgerm cell tumors; high-dose chemotherapy; pediatric tumors; refractory tumors; relapsed tumors; Adolescent; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Child; Child Preschool; Cisplatin; Deoxycytidine; Drug Resistance Neoplasm; Etoposide; Female; Follow-Up Studies; Humans; Ifosfamide; Infant; Male; Neoplasm Recurrence Local; Neoplasms Germ Cell and Embryonal; Oxaliplatin; Paclitaxel; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Salvage Therapypediatric tumorsOxaliplatinSurvival RateLocalOncology030220 oncology & carcinogenesisChild PreschoolFemalerefractory tumorsmedicine.drugmedicine.medical_specialtyAdolescentPaclitaxelThioTEPA03 medical and health sciencesInternal medicinemedicineHumansIfosfamidePreschoolSurvival rateRetrospective StudiesSalvage TherapyChemotherapybusiness.industryInfantmedicine.diseaseGemcitabineCarboplatinNeoplasm RecurrencechemistryDrug Resistance NeoplasmPediatrics Perinatology and Child HealthSettore MED/20NeoplasmGerm Cell and EmbryonalGerm cell tumorsCisplatinNeoplasm Recurrence Localbusinesshigh-dose chemotherapy030215 immunologyFollow-Up StudiesPediatric bloodcancerREFERENCES
researchProduct

Preservation of neuronal function as measured by clinical and MRI endpoints in relapsing-remitting multiple sclerosis: how effective are current trea…

2018

Approved medications for relapsing-remitting multiple sclerosis have shown to be effective in terms of their anti-inflammatory potential. However, it is also crucial to evaluate what long-term effects a patient can expect from current MS drugs in terms of preventing neurodegeneration. Here we aim to provide an overview of the current treatment strategies in MS with a specific focus on potential neuroprotective effects. Areas covered: Randomized, double-blind and placebo or referral-drug controlled phase 2a/b and phase 3 trials were examined; non-blinded phase 4 studies (extension studies) were included to provide long-term data, if not otherwise available. Endpoints considered were expanded…

Oncologymedicine.medical_specialtyAnti-Inflammatory AgentsNeuroimagingDiseaseNeuropsychological TestsPlaceboNeuroprotectionDisability Evaluation03 medical and health scienceschemistry.chemical_compoundMultiple Sclerosis Relapsing-Remitting0302 clinical medicineInternal medicineTeriflunomidemedicineHumansPharmacology (medical)030212 general & internal medicineNeuronsExpanded Disability Status Scalebusiness.industryGeneral NeuroscienceMultiple sclerosismedicine.diseaseMagnetic Resonance ImagingFingolimodNeuroprotective AgentsTreatment OutcomeMultiple sclerosis functional compositechemistryDisease ProgressionNeurology (clinical)businessImmunosuppressive Agents030217 neurology & neurosurgerymedicine.drugExpert Review of Neurotherapeutics
researchProduct

351 Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early stage endometrial cancer

2020

Objective To evaluate the prognostic role of LVSI, evaluated in a semi-quantitative fashion on prognosis of early stage, low risk endometrial cancer (EC). Methods We enrolled patients who underwent surgery for EC between 2003 and 2018 in two referral cancer center. All patients had endometrioid EC, G1-G2, with myometrial invasion Results Among 524 patients, any positive LVSI was found in 57 patients (10.9%) with 6.7% (n=35) focal LVSI and 4.2% (n=22) substantial LVSI. Substantial LVSI was associated to higher rate of G2 (p Conclusions Substantial LVSI represents the strongest independent risk factor for decreased survival and distant relapse, indicating a role for potential hematogenous dis…

Oncologymedicine.medical_specialtyPoor prognosisbusiness.industryEndometrial cancerDistant relapseCancermedicine.diseaseVascular spaceInternal medicinemedicineLymphStage (cooking)Risk factorbusinessPoster
researchProduct

Tumor Size, an Additional Risk Factor of Local Recurrence in Low-Risk Endometrial Cancer: A Large Multicentric Retrospective Study.

2018

ObjectiveThe identification of patients with endometrial cancer (EC) at higher risk for relapse is critical to individualize and better tailor postoperative treatment. No evidence is available regarding the possible association between tumor size (TS) and the risk of local recurrence. The purpose of this study was to analyze the correlation between TS and risk/type of recurrence in EC patients, stratified according to the new European Society of Medical Oncology-European Society of Gynecological Oncology-European Society for Radiotherapy and Oncology classification.MethodsData of patients with histologically proven EC who received primary surgical treatment between November 1999 and June 20…

Oncologymedicine.medical_specialtyPrognostic factormedicine.medical_treatmentRome03 medical and health sciencesEndometrium0302 clinical medicineEndometrial cancerRetrospective StudieRisk FactorsInternal medicinemedicineLocal recurrenceHumansEndometrial NeoplasmRisk factorAgedRetrospective Studies030219 obstetrics & reproductive medicineReceiver operating characteristicTumor sizebusiness.industryRisk FactorEndometrial cancerDistant relapseLocal relapseObstetrics and GynecologyRetrospective cohort studyTumor sizeMiddle Agedmedicine.diseaseEndometrial NeoplasmsRadiation therapyEndometrial cancer; Local recurrence; Local relapse; Tumor size; Vaginal relapse; Oncology; Obstetrics and GynecologyNeoplasm RecurrenceSettore MED/40 - GINECOLOGIA E OSTETRICIALocalReproductive MedicineOncology030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalbusinessVaginal relapseHumanInternational journal of gynecological cancer : official journal of the International Gynecological Cancer Society
researchProduct

Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors

2021

Background: No uniform criteria for a sensitive identification of the transition from relapsing–remitting multiple sclerosis (MS) to secondary-progressive multiple sclerosis (SPMS) are available. Objective: To compare risk factors of SPMS using two definitions: one based on the neurologist judgment (ND) and an objective data-driven algorithm (DDA). Methods: Relapsing-onset MS patients ( n = 19,318) were extracted from the Italian MS Registry. Risk factors for SPMS and for reaching irreversible Expanded Disability Status Scale (EDSS) 6.0, after SP transition, were estimated using multivariable Cox regression models. Results: SPMS identified by the DDA ( n = 2343, 12.1%) were older, more disa…

Oncologymedicine.medical_specialtyRelapsing-RemittingMultiple sclerosis03 medical and health sciencesMultiple Sclerosis Relapsing-Remitting0302 clinical medicineDisease registryRecurrenceRisk Factorsbig dataInternal medicinemedicineHumansdata-driven algorithmMultiple sclerosi030212 general & internal medicinebig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressive; Disease Progression; Humans; Recurrence; Risk Factors; Multiple Sclerosis; Multiple Sclerosis Chronic Progressive; Multiple Sclerosis Relapsing-RemittingSecondary progressiveTransition (genetics)business.industryMultiple sclerosisMultiple Sclerosis Chronic Progressivemedicine.diseaseChronic ProgressiveNeurologybig data; data-driven algorithm; disease registry; Multiple sclerosis; prognosis; secondary progressiveDisease Progressiondisease registrysecondary progressiveSettore MED/26 - NeurologiaNeurology (clinical)prognosisbusinessprognosi030217 neurology & neurosurgery
researchProduct

Clinical and Instrumental Findings and Disability Progression in Primary Progressive and Progressive Relapsing Multiple Sclerosis: A Comparison Study…

2013

Primary Progressive Multiple Sclerosis Progressive relapsing multiple sclerosisSettore MED/26 - Neurologia
researchProduct

Sialotranscriptomics of the argasid tick ornithodoros moubata along the trophogonic cycle

2021

32 páginas, 8 tablas, 6 figuras

Proteomics0301 basic medicineSwinePhysiologyRC955-962Gene ExpressionDisease VectorsProteomicsBiochemistryTranscriptomeMedical Conditions0302 clinical medicineTicksArctic medicine. Tropical medicineGene expressionMedicine and Health SciencesHuman relapsing feverGeneticsbiologyEukaryotaGenomicsProteasesBody FluidsEnzymesBloodInfectious DiseasesFemaleMetabolic PathwaysAnatomyPublic aspects of medicineRA1-1270Transcriptome analysisVitellogeninsMetabolic Networks and PathwaysResearch ArticleIxodidaeArthropoda030231 tropical medicineTickSalivary glandsArthropod Proteins03 medical and health sciencesExocrine GlandsOrnithodoros moubataArachnidaGeneticsAnimalsXenobiotic MetabolismTick ControlOrnithodorosSalivaIllumina dye sequencingIxodesAsfarviridaeImmunityOrganismsPublic Health Environmental and Occupational HealthBiology and Life SciencesComputational BiologyProteinsGenome Analysisbiology.organism_classificationInvertebratesOrnithodoros moubataPhospholipases A2Species InteractionsMetabolism030104 developmental biologyAfricaEnzymologyMetalloproteasesAfrican swine feverTranscriptomeDigestive SystemZoology
researchProduct

Unmet needs and gaps in the identification of secondary progression in multiple sclerosis: a Southern Italy healthcare professionals' perspective

2022

Abstract Objective Multiple sclerosis (MS) is a chronic disease with different clinical courses and a tendency to worsening. The relapsing–remitting MS presents acute onset and relapses of neurological symptoms, followed by their remission. This form can convert to secondary progressive MS (SPMS) with irreversible neurological worsening and disability. The identification of signs, symptoms, markers of progression, and strategies to manage MS patients is mandatory to allow early identification of those at higher risk of conversion to SPMS, for prompt intervention to cope with the progression of the disease. Methods A panel of Italian experts from Southern Italy have reviewed the current know…

Secondary progressive multiple sclerosis (SPMS)DermatologyGeneral MedicineBiomarkerMultiple Sclerosis Chronic ProgressiveMultiple sclerosisPsychiatry and Mental healthMultiple Sclerosis Relapsing-RemittingItalyExpert opinionDiagnosisQuality of LifeDisease ProgressionHumansMultiple sclerosiSettore MED/26 - NeurologiaNeurology (clinical)Neoplasm Recurrence LocalAtrophyDelivery of Health CareBiomarkersDiagnosi
researchProduct

Louseborne relapsing fever in young migrants, sicily, Italy, july-september 2015

2016

To the Editor: During the early 20th century, at the end of World War I, and during World War II, louseborne relapsing fever (LBRF) caused by Borrelia recurrentis was a major public health problem, especially in eastern Europe and northern Africa (1,2). Currently, poor living conditions, famine, war, and refugee camps are major risk factors for epidemics of LBRF in resource-poor countries, such as those in the Horn of Africa (3,4). Increased migration from resource-poor countries and war/violence create new routes for spread of vectorborne diseases. Recently, several cases of LBRF have been reported among asylum seekers from Eritrea in the Netherlands, Switzerland, and Germany (5–8). All of…

Settore MED/07 - Microbiologia E Microbiologia ClinicaLetterrelapsing feverEpidemiologyExpeditedvector-borne infectionslcsh:MedicinemigrantsDengue fever0302 clinical medicinerefugee030212 general & internal medicinebacteriaSicilyLouse-Borne Relapsing Feverbody lousebiologyrefugeesLeptospirosisInfectious DiseasesItalyChillsmedicine.symptomRickettsia conoriizoonoserefugee campsMicrobiology (medical)medicine.medical_specialtyBorrelia recurrentis; Italy; Libya; Sicily; Somalia; bacteria; body louse; louseborne infections; louseborne relapsing fever; migrants; refugee camps; refugees; vector-borne infections; zoonoses; Microbiology (medical); Infectious Diseases; EpidemiologySomalia030231 tropical medicineInfectious DiseaseLibyalouseborne infectionslouseborne infectionlcsh:Infectious and parasitic diseases03 medical and health sciencesInternal medicinemedicinevector-borne infectionlcsh:RC109-216Letters to the EditorLouseborne Relapsing Fever in Young Migrants Sicily Italy July–September 2015louseborne relapsing feverBorrelia recurrentisBorrelia recurrentilouse-borne relapsing feverbusiness.industrylcsh:Rmedicine.diseasebiology.organism_classificationrefugee campzoonosesmigrantImmunologyBorrelia recurrentisbusinessMalaria
researchProduct

Available evidence on re-irradiation with stereotactic ablative radiotherapy following high-dose previous thoracic radiotherapy for lung malignancies

2015

Patients affected with intra-thoracic recurrences of primary or secondary lung malignancies after a first course of definitive radiotherapy have limited therapeutic options, and they are often treated with a palliative intent. Re-irradiation with stereotactic ablative radiotherapy (SABR) represents an appealing approach, due to the optimized dose distribution that allows for high-dose delivery with better sparing of organs at risk. This strategy has the goal of long-term control and even cure. Aim of this review is to report and discuss published data on re-irradiation with SABR in terms of efficacy and toxicity. Results indicate that thoracic re-irradiation may offer satisfactory disease c…

ThoraxRe-Irradiationmedicine.medical_specialtyLung NeoplasmsStereotactic body radiotherapymedicine.medical_treatmentLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapseLung cancer; Re-irradiation; Stereotactic ablative radiotherapy; Stereotactic body radiotherapy; Thoracic relapse; Humans; Lung Neoplasms; Patient Selection; Radiotherapy Dosage; Thorax; Radiosurgery; Oncology; Radiology Nuclear Medicine and ImagingSABR volatility modelRadiosurgeryRadiosurgeryNuclear Medicine and ImagingAblative casemedicineHumansRadiology Nuclear Medicine and imagingLung cancerThoracic relapsebusiness.industryPatient SelectionRetrospective cohort studyRadiotherapy DosageGeneral MedicineThoraxmedicine.diseaseRadiation therapyOncologyRe-irradiationRadiologyStereotactic ablative radiotherapyLung cancerbusinessRadiology
researchProduct